article thumbnail

Govt provides updates on measures to encourage domestic manufacturing

Express Pharma

15,000 crores and a production tenure from FY 2022- 2023 to FY 2027-28, provides financial incentives to 55 selected applicants for manufacturing of identified products under three categories for six years. PLI Scheme for Pharmaceuticals, with a financial outlay of Rs. are manufactured. An incentive amount of Rs.3,215

Immunity 102
article thumbnail

Vyvgart Hytrulo gains first APAC approval in China, redefining CIDP care: GlobalData

Express Pharma

Additionally, it is approved in the EU for gMG and in Japan for gMG and primary immune thrombocytopenia (ITP) under brand names Vyvgart and Vyvdura. per cent from 56,009 in 2023 to 56,163 in 2027.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Immunoglobulin Formulation With Low IgA Content for Primary Immunodeficiency

Pharmacy Times

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Pharmacists are essential in evaluating patient suitability for Gammagard Liquid ERC, considering IgA levels and potential hypersensitivity reactions.

article thumbnail

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Pharmacy Times

Completion Date (Estimated): June 2027 “For people living with advanced ROS1+ lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones,” Janet Freeman-Daily, cofounder and president of The ROS1ders, said in a news release.

article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Dive

Love Employee via Getty Images Dive Brief: Vor Biopharma is licensing rights to an immune disease drug from Chinese biotechnology company RemeGen, it said Wednesday, a little over one month after announcing plans to review strategic alternatives. Data from that trial is expected in 2027. “I

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.

article thumbnail

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

BioPharma Dive

Sarepta is working on a new regimen of immune-suppressing drugs to manage the safety risks, and plans to soon share its findings with the FDA. The company also has $1 billion in senior notes coming due in 2027. The company believes sales in ambulatory patients are likely to annualize at a minimum of $500 million annually through 2027.